• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, April 10, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Why heart contractions are weaker in those with hypertrophic cardiomyopathy

Bioengineer by Bioengineer
October 16, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy (HCM). It is the most common genetic heart disease in the US and affects an estimated 1 in 500 people around the world. A protein called myosin acts as the molecular motor which makes the muscles in the heart contract. Researchers had suspected for some time that the R403Q mutation in some of the myosin genes is among those that play a role in causing HCM. But experiments using mice models failed to show that this was indeed the case. (Mice are often used in experiments because their behaviour, biology and genetic material resemble those of humans).

An international team led by Professor Dilson Rassier from McGill's Department of Kinesiology and Physical Education, has discovered, by working with transgenic rabbits with the R403Q mutation, that in these rabbits, individual myosin molecules and myofibrils (the basic rod-like filaments inside muscles) produce less force and a lower maximum velocity of contraction than those isolated from healthy hearts.

They reached this conclusion by using advanced techniques such as atomic force microscopy and molecular motility assays (which allows them to visualize the movements of these proteins in vitro) to look more closely at what was going on within myosin molecules and also within myofibrils.

"It's been difficult to gain a clear picture of what is going on within the myosin proteins with this mutation, simply because of the technical and experimental limitations of looking closely at objects of this minute size and measuring their force and motility (myosin molecules are about 19 nanometres (0.0000019 centimetres)," explains Rassier. "The results should help clinicians develop drugs and chemicals that target this specific function of myosin in future."

###

The research was funded by the National Institutes of Health (NIH), the Canadian Institutes for Health Research (CIHR) and the Natural Science and Engineering Research Council of Canada (NSERC).

To read "Hypertrophic cardiomyopathy R403Q mutation in rabbit β-myosin reduces contractile function at the molecular and myofibrillar levels" by Susan Lowey, et al in PNAS: DOI/10.1073/PNAS.1802967115

Contacts:

Dilson Rassier, Dept. of Kinesiology and Physical Education, McGill University

[email protected]

(English interviews only)

Katherine Gombay, Media Relations, McGill University

[email protected], 514 398-2189

http://www.mcgill.ca/newsroom/

Tweets by mcgillu

Media Contact

Katherine Gombay
[email protected]
@McGillU

http://www.mcgill.ca

https://www.mcgill.ca/newsroom/channels/news/why-heart-contractions-are-weaker-those-hypertrophic-cardiomyopathy-290647

Related Journal Article

http://dx.doi.org/10.1073/PNAS.1802967115

Share12Tweet7Share2ShareShareShare1

Related Posts

Boosted WNT10B/FOXO6 Drives Kidney Inflammation, Fibrosis

April 10, 2026

Dual AAV8 Therapy Halts Retinal Degeneration Death

April 10, 2026

Anticoagulant Adherence Impacts Valve Surgery Outcomes

April 10, 2026

Study Suggests Artificial Sweeteners’ Negative Effects Could Impact Future Generations in Mice

April 10, 2026
Please login to join discussion

POPULAR NEWS

  • Boosting Breast Cancer Risk Prediction with Genetics

    45 shares
    Share 18 Tweet 11
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    44 shares
    Share 18 Tweet 11
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1012 shares
    Share 400 Tweet 250
  • Revolutionary Theory Transforms Quantum Perspective on the Big Bang

    40 shares
    Share 16 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Boosted WNT10B/FOXO6 Drives Kidney Inflammation, Fibrosis

Dual AAV8 Therapy Halts Retinal Degeneration Death

Stage II Melanoma: CBL Emerges as Key Driver

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.